Eumentis is a biopharmaceutical company that develops novel drugs for the treatment of neurodevelopmental and neurodegenerative disorders.The Company's lead product candidate, EM-036, is a novel proprietary nitro-aminoadamantane N-methyl-d-aspartate type-glutamate receptor (NMDAR) antagonist first being developed for the treatment ofchildren and adults with Autism Spectrum Disorder (ASD). EuMentis is also exploring other indications for EM-036.

Biotechnology

Health Care

Eumentis Therapeutics

Eumentis Therapeutics' headquarters in Boston, MA, United States

Eumentis Therapeutics

Org chart

Teams

Offices

Similar companies